The FDA approved a regimen of one maintenance dose every 8 weeks for lebrikizumab-lbkz in adults and children aged 12 years and older who weigh at least 88 pounds with moderate to severe atopic dermatitis, according to a press release.
Lebrikizumab-lbkz (Ebglyss, Eli Lilly) 250 mg/2 mL single injection, a targeted interleukin-13 inhibitor, is already approved for a once-monthly maintenance dose. The expanded dosing indication gives patients the option of receiving fewer injections while maintaining disease control, according to the release.
“What excites me most is the additional flexibility

Randomized controlled trials may not properly capture ultraprocessed foods’ health effects due to their designs and limitations, experts suggest.
In a commentary published in Science, Faidon Magkos, MSc, PhD, a professor of obesity and metabolism at University of Copenhagen in Denmark, and colleagues used five clinical trials in the United States, United Kingdom, Denmark and Japan to demonstrate their case.
The findings of these trials on ultraprocessed foods (UPFs) “have been highly publicized and widely communicated, often in ways that suggest that ultraprocessing is inherently

In patients with severe hypertriglyceridemia, olezarsen lowered triglycerides and reduced acute pancreatitis events compared with placebo, researchers reported at the European Atherosclerosis Society Congress.
André Zimerman, MD, PhD, professor of cardiology and head of clinical trials at Hospital Moinhos de Vento, Moinhos de Vento Medical School, Porto Alegre, Rio Grande do Sul, Brazil, presented on behalf of the TIMI Study Group a pooled analysis of 455 patients (mean age, 52 years; 20% women) with severe hypertriglyceridemia, defined as triglyceride level more than 880 mg/dL, or 10 mmol/L,

NEW ORLEANS —Adolescents with new-onset type 2 diabetes and obesity were more likely to achieve an HbA1c of less than 6% at 1 year with sleeve gastrectomy compared with treat-to-target medical therapy, researchers reported.
Amy S. Shah, MD, MS, FNLA, director of the division of endocrinology at Cincinnati Children’s Hospital, said the SURPASS-PEDS trial showed tirzepatide (Mounjaro/Zepbound, Eli Lilly) improved HbA1c by about 2.3 percentage points while also reducing BMI for children with type 2 diabetes. Shah said tirzepatide is the first pharmacotherapy option that can lower HbA1c and BMI

ORLANDO — There is a bidirectional relationship between asthma control and depressive symptoms, according to a poster presented at the American Thoracic Society International Conference.
“People with asthma have a higher incidence of depression,” Brittany Duchene, MSc, MD, pulmonary and critical care physician, Larner College of Medicine at the University of Vermont, told Healio.
“People with depression have a higher incidence of asthma. It’s very complicated. We’re not sure why. There are many, many reasons that could potentially be causing that,” she said.
According to Duchene and colleagues,

The 2026 FIFA World Cup will be the largest — and longest — in the tournament’s storied 96-year history.
An expanded field of 48 nations will play a record 104 combined matches over 39 days. Standing room-only crowds will fill 16 venues — spread for the first time across three countries — and a record-breaking 6 billion people around the globe are expected to tune in via television or digital platforms.
One of them — Filippo Milano, MD, PhD — will have a rather unorthodox rooting interest.
“Everybody but France,” he declared.
Milano, a hematologist-oncologist at Fred Hutch Cancer Center, flashed

Patients with IgG4-related disease who received obexelimab demonstrated a 56% reduction in flare risk compared with those given placebo at 52 weeks, according to data presented at the EULAR 2026 Congress.
“The most relevant unmet need in our clinical management of patients with IgG4-related disease is the chronic and relapsing nature of IgG4-related disease,” Emanuel Della Torre, MD, of the unit of immunology, rheumatology, allergy and rare diseases at the IRCCS San Raffaele Scientific Institute in Milan, Italy, told attendees. “IgG4-related disease keeps on coming back.”